mergers & acquisitions | GenomeWeb

mergers & acquisitions

Synthetic lipids developer Anatrace said the addition of Molecular Dimensions' products to its menu will add to its array of drug discovery tools.

Privately held Miragen will pick up Signal's Nasdaq listing, and the combined company is scheduled to begin trading today.

The acquisition of GeneWorks' oligo business widens IDT's reach in the Asia-Pacific region, the company said.

Novartis will retain Genoptix's biopharma business, which will be renamed Navigate BioPharma Services.

Abbott's commitment to closing the deal is still uncertain, but Alere's CEO said the regulatory clearance marks a "significant milestone." 

Through the deal, Ginkgo has picked up Gen9's manufacturing platform and suite of proprietary technologies, software, and informatics tools for DNA synthesis and assembly.

The deal is expected to strengthen WuXi Apptec's capabilities in target validation, as well as lead discovery and optimization.

Terms of the deal have not been disclosed, but the firms expect to finalize the acquisition in the first quarter of 2017.

The cloud-based personalized medicine software company will stay in Cambridge, Massachusetts and will become a wholly-owned subsidiary of the institute.

Tulip Diagnostics Private provides in vitro diagnostic reagents, kits, and instruments to labs, and government and private healthcare facilities in India.

Pages

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.